Ex vivo analyses of the liver samples showed an 18% decrease in P450 content, a 60% increase in palmitoyl-CoA β-oxidation activity, and a 41% and 23% decrease in CYP3A protein expression and activity, respectively. Furthermore, liver samples of bortezomib treated rats had little change in CYP2B and CYP4A protein levels and activities. To address the likelihood of clinical drug-drug interactions, the P450 inhibition potential of bortezomib and its major deboronated metabolites M1, M2, and their dealkylated metabolites M3 and M4 was evaluated in human liver microsomes for the major P450 isoforms 1A2, 2C9, 2C19, 2D6, and 3A4/5. Bortezomib, M1, and M2 were found to be Goat anti-rat CYP2B and CYP4A polyclonal antibodies and rat CYP2B1 and CYP3A1 supersomes were purchased from BD Gentest (Woburn, MA Microsomes and peroxisomes enriched fractions were prepared in house following published protocols (Guengerich 1989 , Small et al. 1985 . In the peroxisomes preparation, the liver homogenates were first centrifuged at 6,000g for 10 min to remove mitochondria and other heavy cellular fragments. Then a 30 min centrifugation at 30,000g was applied to collect the peroxisomes enriched fractions. Microsomes and peroxisomes enriched fractions prepared from the livers of female rats treated with 200 mg/kg clofibric acid in 2.5 mL Mazola ® oil in house for 4 days were used as positive controls in the CYP4A1 and peroxisomal activity assay, respectively. The total P450 content in microsomes was determined using the method described by Omura and Sato
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the metabolites are not pharmacologically active. Like many other cancer drugs, bortezomib is a cytotoxic agent with a narrow therapeutic index. Thus, it is important to understand the metabolism of bortezomib and the consequences of inhibition or induction of that metabolism. Furthermore, for cancer patients on multiple drug therapy, adverse effects may arise if bortezomib affects the enzymes metabolizing these co-administered drugs. Therefore, understanding the enzymes which affect the metabolism of bortezomib and the enzymes which are affected by bortezomib would help to predict possible drugdrug interactions.
Bortezomib was found to be primarily metabolized by CYP3A4 and CYP2C19 (Pekol et al. 2005 , Uttamsingh et al. 2005 . In this study, the effect of bortezomib on P450 enzymes was evaluated ex vivo in Sprague-Dawley rats. Rats were selected as the ex vivo model because liver enlargement was observed in preclinical toxicology studies in rats but not in other species such as monkeys. The microsomal activities and protein levels of major inducible P450s (2B1/2, 3A1/2, and 4A1/3) and peroxisomal palmitoylCoA oxidation activity in rat liver were determined. The P450 inhibitory potential of bortezomib and its major metabolites, M1, M2, M3, and M4 on the major P450 isoforms 1A2, 2C9, 2C19, 2D6, and 3A4/5 as well as the time-dependent CYP3A4/5 inhibition potential were evaluated in human liver microsomes.
This article has not been copyedited and formatted. The final version may differ from this version. S-mephenytoin was purchased from Biomol, Inc. (Plymouth Meeting, PA). Human, naïve rat, phenobarbital or dexamethasone induced rat liver microsomes, and rabbit antirat CYP3A polyclonal antibody were purchased from Xenotech, LLC (Lenesa, KS).
Goat anti-rat CYP2B and CYP4A polyclonal antibodies and rat CYP2B1 and CYP3A1 supersomes were purchased from BD Gentest (Woburn, MA). [ 14 C] palmitoyl-CoA, ECL plus Western blotting detection reagents were purchased from Amersham (Piscataway, NJ). Nupage Novex Bis-tris gels and electrophoresis reagents kit were purchased from Invitrogen (Carlsbad, CA).
This article has not been copyedited and formatted. The final version may differ from this version. Microsomes and peroxisomes enriched fractions were prepared in house following published protocols (Guengerich 1989 , Small et al. 1985 . In the peroxisomes preparation, the liver homogenates were first centrifuged at 6,000g for 10 min to remove mitochondria and other heavy cellular fragments. Then a 30 min centrifugation at 30,000g was applied to collect the peroxisomes enriched fractions. Microsomes and peroxisomes enriched fractions prepared from the livers of female rats treated with 200 mg/kg clofibric acid in 2.5 mL Mazola ® oil in house for 4 days were used as positive controls in the CYP4A1 and peroxisomal activity assay, respectively. The total P450 content in microsomes was determined using the method described by Omura and Sato (1964) . Protein concentrations in microsomes or peroxisomal fractions were determined using the BCA Protein Assay kit (Pierce, Rockford, IL).
Testosterone and lauric acid oxidation assays. Rat liver microsomes (0.25 mg/mL), in triplicate, were pre-warmed for 5 min at 37°C in 0. stopped by the addition of equal volume of acetonitrile containing 1 µ M internal standards (6β-hydroxydianabol and 10-hydroxydecanoic acid for the testosterone and lauric acid assay, respectively). After placing the sample on ice for 30 min, the precipitated proteins were removed via a 10 min centrifugation at 3,000g. Metabolites 16β-and 6β-hydroxytestosterone, and 12-hydroxylauric acid were analyzed using an Applied Biosystems API 4000 LC/MS/MS system and a Phenomenex Synergi C18 column (75 x 4.6 mm). Metabolite separation was achieved with a gradient consisting of 0.1 % formic acid/water (mobile phase A) and 0.1 % formic acid/acetonitrile (mobile phase B) at a flow rate of 1.0 mL/min, specifically, 5% of mobile phase B was applied for 0.5 min after injection and increased linearly to 95% B from 0.5 to 3.5 min. Mobile phase B was held at 90% from 3.5 to 3.6 min and the column was re-equilibrated to 5% B from 3.6 to 5.0 min. Positive and negative ion spray modes were applied to 6β-, 16β- were transferred into scintillation vials containing 5 mL of Ultima Flo M cocktail (Perkin Elmer, Boston, MA), and the total radioactivity was counted using a Beckman LS6500 scintillation counter. An identical control set of samples was incubated on ice (Lazarow 1981 were blocked in 5% non-fat dry milk/PBST for 1 hour before being incubated with primary antibodies (1:1000 diluted in 5% non-fat dry milk/PBST) overnight at 4°C.
After washing three times in PBST, the membranes were incubated with the secondary antibodies for 1 hour, followed by three washes in PBST and once in TBS to remove the excess second antibodies. ECL plus Western Blotting Detection Reagents were then used to detect proteins and the chemiluminescent signals were captured on Kodak Biomax films (Rochester, NY). Images were quantitatively analyzed using the NIH Images software (NIH, Bethesda, MD).
This article has not been copyedited and formatted. The final version may differ from this version. Troleandomycin (10 µM) was included as a positive control. The results were processed following a method described by Kitz and Wilson (1962) .
Statistical analysis Data were processed using Microsoft Excel (Microsoft, Redwood, WA) to calculate means and standard deviations. Student t-test with 95% confidence (p<0.05) was performed on data from different treatment groups to determine any significant differences between the means of the treatment groups.
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RESULTS

Rat ex vivo liver enzyme characterization
Total P450 content in rat liver microsomes. Body weights, liver weights, and P450 contents were measured. Results in Table 1 showed that bortezomib-treated rats had an average liver weight of 13.8 g compared to the vehicle control group of 10.2 g. This represented a 35% increase in liver weight whereas the body weights were barely changed (291 g vs. 302 g in the bortezomib-treated rats). On the other hand, microsomes prepared from bortezomib-treated rats had an average total P450 content of 0.503 nmol/mg protein compared to 0.614 nmol/mg protein for the vehicle control group, resulting in an 18% decrease in P450 content.
CYP2B1/2, CYP3A1/2, CYP4A1/3 activities and protein expression levels in rat liver microsomes. Testosterone 16β-hydroxylation, 6β-hydroxylation, and lauric acid 12-hydroxylation are mediated by CYP2B1/2, CYP3A1/2, and CYP4A1/3 in rats, respectively. The rates of formation of these metabolites were measured to evaluate the effect of bortezomib on rat P450s. Results from this study showed little difference in CYP2B1/2 activities between the control-and the bortezomib-treated rats (97.5 ± 9.5 vs.
96.9 ± 12.8 pmol/min/mg protein, Table 1 ). In addition, quantitative image analysis of CYP2B1/2 Western blots (Table 1 and Figure 2) showed that the microsomes from the vehicle control group had an average band intensity of 1.49 ± 0.08 compared to 1.23 ± This article has not been copyedited and formatted. The final version may differ from this version. Figure 2) showed that the control group had an average CYP3A1/2 band intensity of 1.64 ± 0.04 compared to that of 0.97 ± 0.34 in the bortezomib-treated group. This was a 41% decrease in 3A1/2 protein expression level which could be attributed to the bortezomib treatment in rats. The CYP4A1/3 activity in the vehicle control rats was 1286 ± 236 pmol/min/mg protein, whereas the bortezomib-treated rats had an average specific activity of 1418 ± 379 pmol/min/mg protein (Table 1 ). In the Western blots (Table 1 and Figure 2), the vehicle control rats showed an average CYP4A1/3 band intensity of 2.24 ± 0.58 and the bortezomib-treated rats showed an average band intensity of 1.93 ± 0.38. This 10% increase in CYP4A1/3 activity and 14% decrease in the CYP4A1/3 protein expression in bortezomib treated rats was statistically insignificant (Student t test, p<0.05).
Fatty acid β -oxidation activity in rat liver peroxisomal fractions. Results from this study showed that vehicle control rats had an average peroxisomal activity of 1.57 ± 0.43 nmol/min/mg protein, whereas the bortezomib-treated rats had an average activity of 2.57
This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) , representing a 60% increase in peroxisomal activity in the bortezomib treated rats. Female rats treated in house with clofibric acid, the prototypical CYP4A and peroxisomal acyl-CoA oxidase inducer, were included in this study as a positive control. An average peroxisomal activity of 21.7 nmol/min/mg protein was observed in the clofibric acid treated rats as compared to the oil-diet vehicle control rats which had a specific activity of 2.42 nmol/min/mg protein -a 9-fold increase.
It has been suggested that rats treated with an oil diet have slightly higher (50% increase) basal peroxisomal activity compared to rats fed a standard laboratory diet (Huber et al. 1997 ). In our study, it was indeed the oil-diet control rats that had higher peroxisomal activity than the chow-diet control rats.
CYP inhibition studies in human liver microsomes
The CYP inhibition potential of bortezomib and its major metabolites M1 -M4 was studied in human liver microsomes using drug-like probe substrates. The results presented in Table 2 the known selective CYP inhibitors are also presented in Table 2 for comparison. Since the CYP3A substrates used in this study (testosterone and midazolam) could not distinguish the CYP3A4 from the CYP3A5, the CYP3A activities in human liver microsomes were expressed as CYP3A4/5, although CYP3A4 is the major CYP3A isoform in liver.
In the time-dependent inhibition study, the percent of CYP3A4/5 activities remaining in Peroxisomal acyl-CoA oxidase (β-oxidation of fatty acids) is also an inducible enzyme which often attributes to liver enlargement. In our preclinical in vivo toxicity study, an increase in liver weight (35%) following a repeat dose of bortezomib was observed in both male and female rats. Thus, the primary goal for this study was to investigate if the liver enlargement was caused by the induction of CYP2B1/2, 3A1/2, 4A1/3, and/or peroxisomal acyl-CoA oxidase. Female rats were chosen because their lower hepatic CYP3A expression makes them a more sensitive gender for studying P450 induction, especially for CYP3A. Compared to the vehicle control group, the bortezomib treated rats showed no changes in CYP2B1/2 and 4A1/3 activities and protein levels. However, a 23% decrease in CYP3A1/2 activity was observed but it was not statistically significant. This could be due to the variability of the data and the small size of the data set. A decrease in the P450 content and the CYP3A1/2 protein expression, and an increase in the palmitoyl CoA β -oxidation activity were also observed in bortezomibtreated rats. If these changes were normalized to the total liver weight by assuming that the yields of microsomes or peroxisomes (mg protein / gram of liver) were similar across all of the treatment groups, the changes in the total P450 content would become insignificant while the increase of palmitoyl CoA β -oxidation activity would become apparent. Because the microsomal content may vary upon drug treatment in rats (Carlile et al. 1999 ) and the recovery of microsomes preparation was not tracked in this study, our to the 9-fold induction observed with the positive control compound clofibric acid, the 60% increase by bortezomib is mild. The increase in liver weight may also be attributed to the accumulation of ubiquitinated protein in hepatocytes, as hypertrophy not hyperplasia was observed in these liver samples.
It is known that proteasomes mediate degradation of some P450 isoforms including 1A2, 2E1, 3A, and 4A but not 1A1, 2B1/2, or NADPH reductase (Roberts, 1997 , Correia et al. 2004 ). In our study the CYP2B1/2 activity and the protein expression level in rats were indeed not affected by the proteasome inhibitor bortezomib. CYP1A and 2E were not included in the present study because they are relatively minor enzymes compared to the CYP2B and 3A in rats. It is interesting to note that the CYP4A1/3 activities and protein expression levels in our study were unchanged, whereas Roberts (1997) showed that proteasome inhibitors could enhance CYP4A degradation in rat hepatocyte cultures.
Studies by Zangar and colleagues (2003) also showed that rat hepatocytes treated with proteasome inhibitors resulted in a decrease of CYP3A protein and mRNA levels.
However this is contrary to the CYP3A-ubiqutin-proteasome pathway, thus suggesting CYP3A may be degraded by multiple pathways, or proteasomes could be responsible for the degradation of proteins which suppress CYP3A expression. In our study we also observed a 41% decrease in CYP3A protein expression and a 23% decrease in CYP3A activity although the latter is not statistically significant. Although a change in profiling and CYP phenotyping studies, bortezomib was found to be primarily metabolized by CYP3A4/5 and 2C19 (Pekol et al. 2005 , Uttamsingh et al. 2005 . This explains that bortezomib, being a substrate of CYP3A4/5 and 2C19, is also a mild reversible inhibitor of these two enzymes. The secondary dealkylated metabolites M3
and M4 did not inhibit any of the five CYPs suggesting that the boron containing chain of bortezomib is responsible for the mild CYP inhibition.
Reactive metabolites are often generated by P450-mediated bioactivation of drugs. These reactive metabolites could covalently bind to microsomes or form a metabolite intermediate complex (MIC) to inactivate microsomal activity and thus result in an increase in exposure of that compound. Bortezomib was found not to cause exposure change in our preclinical animal species, thus in the present study time-dependent inhibition was focused on CYP3A4/5 -the primary CYP metabolizing bortezomib as well as over 50% of drugs on the market (Uttamsingh et al. 2005 , Kwon 2001 ). In our study, the observation of no time-dependent inhibition of CYP3A4/5 by bortezomib and its major metabolites suggests that there were no reactive metabolites being generated that would interact with CYP3A4/5. Consistent with that, bortezomib was found not to cause exposure change in preclinical species.
